![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Journey Medical Corporation | NASDAQ:DERM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -0.91% | 5.46 | 5.00 | 5.75 | 5.64 | 5.32 | 5.49 | 30,739 | 00:35:33 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (date of earliest event reported): January 7, 2019
DERMIRA, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-36668 |
|
27-3267680 |
(State or other jurisdiction of incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification Number) |
|
|
|
|
275 Middlefield Road, Suite 150 |
|
|
|
Menlo Park, California |
|
|
94025 |
(Address of Principal Executive Offices) |
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (650) 421-7200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
Dermira, Inc. (“ Dermira ”) hereby reports that, to date, it has secured payer coverage of QBREXZA™ (glycopyrronium) cloth for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older for approximately 70% of the total U.S. commercial lives (calculated based on Dermira data on file).
The information furnished in this Current Report under Item 8.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
DERMIRA, INC. |
|
|
|
|
|
|
|
Date: January 7, 2019 |
By: |
/s/ Andrew L. Guggenhime |
|
|
Name: Andrew L. Guggenhime |
|
|
Title: Chief Financial Officer |
1 Year Journey Medical Chart |
1 Month Journey Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions